Kymera Therapeutics Inc (NASDAQ: KYMR) stock jumped 7.88% on Friday to $19.43 against a previous-day closing price of $18.01. With 0.95 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.64 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.85 whereas the lowest price it dropped to was $18.07. The 52-week range on KYMR shows that it touched its highest point at $39.85 and its lowest point at $9.60 during that stretch. It currently has a 1-year price target of $39.00. Beta for the stock currently stands at 1.95.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KYMR was up-trending over the past week, with a rise of 33.82%, but this was up by 63.41% over a month. Three-month performance dropped to -4.43% while six-month performance fell -34.47%. The stock lost -33.44% in the past year, while it has lost -22.16% so far this year. A look at the trailing 12-month EPS for KYMR yields -2.88 with Next year EPS estimates of -3.23. For the next quarter, that number is -0.31. This implies an EPS growth rate of 10.47% for this year and -25.67% for next year. EPS is expected to grow by 1.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -56.21%.
Float and Shares Shorts:
At present, 55.04 million KYMR shares are outstanding with a float of 48.14 million shares on hand for trading. On Oct 30, 2023, short shares totaled 8.1 million, which was 14.60% higher than short shares on Sep 28, 2023. In addition to Dr. Bruce L. Booth DPHIL, Ph.D. as the firm’s Co-Founder & Chairman, Dr. Nello Mainolfi M.D., Ph.D. serves as its Co-Founder, President, CEO & Director.
Through their ownership of 105.97% of KYMR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 51.32% of KYMR, in contrast to 41.52% held by mutual funds. Shares owned by individuals account for 21.27%. As the largest shareholder in KYMR with 9.12% of the stake, BVF Partners LP holds 5,054,898 shares worth 5,054,898. A second-largest stockholder of KYMR, T. Rowe Price Associates, Inc., holds 4,980,309 shares, controlling over 8.99% of the firm’s shares. Wellington Management Co. LLP is the third largest shareholder in KYMR, holding 4,823,329 shares or 8.70% stake. With a 4.83% stake in KYMR, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,677,387 shares are owned by the mutual fund manager. The Vanguard Health Care Fund, which owns about 2.60% of KYMR stock, is the second-largest Mutual Fund holder. It holds 1,442,019 shares valued at 16.83 million. SPDR S&P Biotech ETF holds 2.35% of the stake in KYMR, owning 1,301,069 shares worth 15.18 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KYMR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With KYMR analysts setting a high price target of $93.00 and a low target of $16.00, the average target price over the next 12 months is $39.00. Based on these targets, KYMR could surge 378.64% to reach the target high and fall by -17.65% to reach the target low. Reaching the average price target will result in a growth of 100.72% from current levels.
Summary of Insider Activity:
Insiders traded KYMR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 34 over the past year. The total number of shares bought during that period was 178,000 while 918,820 shares were sold.